Recognition
Recognition

Three Partners Recognized for Excellence in STEM

June 25, 2020
Partners Brenda Danek, Inge Osman, and Elizabeth Richards named “Women Worth Watching in STEM 2020.”

Brenda Danek, Inge Osman, and Elizabeth Richards have been named to Profiles in Diversity Journal’s “Women Worth Watching in STEM 2020” list. The award honors the achievements of high-performing women leaders in STEM fields who demonstrate a commitment to advancing gender diversity in their professions. 

Brenda Danek, Ph.D., a partner in the Intellectual Property Litigation Practice in the Chicago office, successfully represents clients in cases focusing on pharmaceuticals, biotechnology, antibodies, and medical devices. Her practice focuses primarily on patent litigation, with particular focus on antibody, biotechnology, and Hatch-Waxman litigation. Dr. Danek deftly translates complex technical and scientific concepts for clients, attorneys, judges, and jurors in litigating patent matters before both district court and proceedings before the US Patent and Trademark Office, including devising strategies for parallel proceedings.

Inge Osman, a partner in the Washington, D.C. office, advises domestic and multinational clients on their highest-stakes intellectual property litigation, including before federal district and appellate courts, as well as before the Patent Trial and Appeal Board (PTAB). Combining sophisticated technical knowledge and significant trial experience, Ms. Osman helps clients achieve their desired outcomes in complex patent litigation. She has successfully represented clients in matters involving a range of technologies, including pharmaceuticals, biotechnology, antibodies, medical devices, semiconductors, liquid crystal display technologies, biometric scanning devices, information technology, and call processing systems.

Elizabeth Richards, a partner in the Healthcare & Life Science practice in the Washington, D.C. office, advises clients in all facets of FDA oversight and regulation. As Latham’s legal lead for clinical trials, Ms. Richards counsels clients in complex regulatory matters involving clinical development, and negotiates complex agreements between her clients and clinical sites to enable the conduct of medical research. Her work as a life sciences lawyer today paves the way for innovative life sciences companies as they navigate the legal and regulatory labyrinth required to bring new therapies to market. In 2019 alone, Ms. Richards assisted more than 160 clients in the race to develop new therapeutics and other medical products.

Endnotes